Haskell Regional Hospital, Inc

Summary Statement of Deficiencies D0000 The recertification survey was performed on 03/17,18,19,20/2026. The laboratory was found out of compliance with the following CLIA Conditions: 493.1215; D5024: Hematology 493.1210; D5016: Routine Chemistry 493.1403; D6000: Laboratory Director; Moderate Complexity Testing D3025 REQUIREMENTS FOR TRANSFUSION SERVICES CFR(s): 493.1103(d) Investigation of transfusion reactions. The facility must have procedures for preventing transfusion reactions and when necessary, promptly identify, investigate, and report blood and blood product transfusion reactions to the laboratory and, as appropriate, to Federal and State authorities. This STANDARD is not met as evidenced by: Based on a review of records, nursing policy, and interview with the technical consultant, the facility failed to ensure written policies were followed for preventing transfusion reactions for one of six units of packed red-blood cells transfused. Findings include: (1) On 03/18/2026 at 10:00 am, the technical consultant stated blood transfusions were performed by nursing staff; (2) A review of the hospital policy titled, "Administering Blood or Blood Products" stated: (a) "Vital signs must be taken and documented on the transfusion administration record just prior to administering blood or blood products, then"; (b) "after first fifteen minutes of transfusion": (c) "hourly until transfusion is complete"; (d) "and then upon completion of the transfusion"; (e) "One hour post infusion"; (f) "Each unit of blood must be completely infused within four (4) hours of removing from the blood bank refrigerator". (3) A review of transfusion records for six units transfused, identified the policy had not been followed for one of six units as follows: (a) Unit #W091026116010 - The unit was issued on 02/14/2026 at 09:01 pm and was stopped Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 8 -- on 02/15/2026 at 01:30 am; (i) The unit was infused in 4 hours and 29 minutes. (4) The records were reviewed with the technical consultant who stated on 03/18/2026 at 10:00 am, the unit had not been given according to policy. D5016 ROUTINE CHEMISTRY CFR(s): 493.1210 If the laboratory provides services in the subspecialty of Routine Chemistry, the laboratory must meet the requirements specified in 493.1230 through 493.1256, 493. 1267, and 493.1281 through 493.1299. This CONDITION is not met as evidenced by: Based on a review of records, policies and procedures, and interview with the technical consultant and testing person #1, the laboratory failed to ensure the requirements were met for the subspecialty of Routine Chemistry for High Sensitivity Troponin I testing during the review period of 11/25/2025 through the current date. Findings include: (1) The laboratory failed to have a written procedure for one of two new test systems introduced into the laboratory. Refer to D5401; (2) The laboratory failed to perform two levels of QC (quality control) materials for 54 of 58 days of patient High Sensitivity Troponin I testing. Refer to D5447. D5024 HEMATOLOGY CFR(s): 493.1215 If the laboratory provides services in the specialty of Hematology, the laboratory must meet the requirements specified in 493.1230 through 493.1256, 493.1269, and 493. 1281 through 493.1299. This CONDITION is not met as evidenced by: Based on a review of records and interview with the technical consultant and testing person #1, the laboratory failed to ensure the requirements were met for the specialty of Hematology for CBC testing during the review period of September 2024 through the current date. Findings include: (1) The laboratory failed to demonstrate a the performance specifications for one of two new test methods introduced into the laboratory in 2024. Refer to D5421. D5211 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(a) The laboratory must review and evaluate the results obtained on proficiency testing performed as specified in subpart H of this part. This STANDARD is not met as evidenced by: Based on a review of records and interview with the technical consultant, the laboratory failed to review and evaluate proficiency testing results for three of five Chemistry proficiency testing events reviewed in 2024 and 2025. Findings include: I. BIASES (1) On 03/17/2026, a review of Chemistry proficiency testing records for 2024 (second, and third events) and 2025 (first, second, and third event) identified the following biases (biases were identified using the SDI (Standard Deviation Index) values assigned by the proficiency program) for three of five events: (a) 2024 - -- 2 of 8 -- Chemistry Core 2nd Event (i) Aspartate Aminotransferase (AST) - five of five results exhibited a positive bias (aa) Sample CH-06 - SDI of 4.5 (bb) Sample CH-07 - SDI of 4.8 (cc) Sample CH-08 - SDI of 2.7 (dd) Sample CH-09 - SDI of 3.6 (ee) Sample CH- 10 - SDI of 4.7 (ii) Alanine Aminotransferase (ALT) - five of five results exhibited a positive bias (aa) Sample CH-06 - SDI of 6.7 (bb) Sample CH-07 - SDI of 6.0 (cc) Sample CH-08 - SDI of 1.3 (dd) Sample CH-09 - SDI of 6.6 (ee) Sample CH-10 - SDI of 5.3 (b) 2024 - Chemistry Core 3rd Event (i) Aspartate Aminotransferase (AST) - five of five results exhibited a positive bias (aa) Sample CH-11 - SDI of 5.0 (bb) Sample CH-12 - SDI of 4.3 (cc) Sample CH-13 - SDI of 4.8 (dd) Sample CH-14 - SDI of 4.5 (ee) Sample CH-15- SDI of 5.0 (ii) Alanine Aminotransferase (ALT) - five of five results exhibited a positive bias (aa) Sample CH-11 - SDI of 6.6 (bb) Sample CH- 12 - SDI of 6.5 (cc) Sample CH-13 - SDI of 6.3 (dd) Sample CH-14 - SDI of 7.2 (ee) Sample CH-15- SDI of 6.9 (c) 2025 - Chemistry Core 1st Event (i) Aspartate Aminotransferase (AST) - five of five results exhibited a positive bias (aa) Sample CH-01 - SDI of 2.7 (bb) Sample CH-02 - SDI of 2.9 (cc) Sample CH-03 - SDI of 3.2 (dd) Sample CH-04 - SDI of 2.3 (ee) Sample CH-05 - SDI of 3.6 (ii) Alanine Aminotransferase (ALT) - five of five results exhibited a positive bias (aa) Sample CH-01 - SDI of 6.2 (bb) Sample CH-02 - SDI of 6.5 (cc) Sample CH-03 - SDI of 7.2 (dd) Sample CH-04 - SDI of 3.2 (ee) Sample CH-05 - SDI of 7.2 (2) There was no evidence in the records to prove the biases had been identified and addressed; (3) The records were reviewed with the technical consultant, who stated on 03/17/2026 at 11: 40 am, the biases had not been identified and addressed. D5401 PROCEDURE MANUAL CFR(s): 493.1251(a) (a) A written procedures manual for all tests, assays, and examinations performed by the laboratory must be available to, and followed by, laboratory personnel. Textbooks may supplement but not replace the laboratory's written procedures for testing or examining specimens. This STANDARD is not met as evidenced by: Based on a review of policies and procedures and interview with the technical consultant and testing person #1, the laboratory failed to have a written procedure for one of two new test systems introduced into the laboratory. Findings include: (1) On 03/17/2026 at 02:23 pm, the technical consultant and testing person #1 stated the following: (a) The laboratory began performing High Sensitivity Troponin I testing using the iSTAT1 analyzer and hs-TnI cartridge on 11/25/2025. (2) A review of the laboratory's written procedure manual identified that there was no procedure available for the High Sensitivity Troponin I testing; (3) Interview with the technical consultant and testing person #1 on 03/19/2026 at 10:30 am confirmed that the laboratory did not have a written policy and procedure for High Sensitivity Troponin I testing. D5421 ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(1) (b) Each laboratory that introduces an unmodified, FDA-cleared or approved test system must do the following before reporting patient test results: (b)(1)(i) Demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (b)(1)(i) (A) Accuracy. (b)(1)(i)(B) Precision. (b)(1)(i)(C) Reportable range of test results for the test system. (b)(1)(ii) Verify that the manufacturer's reference intervals (normal -- 3 of 8 -- values) are appropriate for the laboratory's patient population. This STANDARD is not met as evidenced by: Based on a review of records and interview with the technical consultant and testing person #1, the laboratory failed to demonstrate the performance specifications for one of two new test methods introduced into the laboratory in 2024. Findings include: (1) On 03/17/2026 at 02:15 pm, the technical consultant and testing person #1 stated the laboratory began performing CBC (Complete Blood Count) testing using the Sysmex XN 1000 analyzer on 09/03/2024; (2) On 03/19/2026, a review of records identified no evidence the performance specifications had been demonstrated prior to putting the analyzer into use for patient testing; (3) Interview with the technical consultant and testing person #1 on 03/19/2026 at 02:25 pm confirmed there was no documentation to substantiate the performance specifications had been demonstrated prior to beginning patient testing; (4) The following were examples of patient testing performed: (a) Patient # 10023658 - testing performed on 09/04/2024 (b) Patient # 10023681- testing performed on 09/05/2024 (c) Patient #10023792 - testing performed on 09/13/2024 (d) Patient # 10023817 - testing performed on 09/16/2024 (e) Patient # 10023722 - testing performed on 09/22/2024 (f) Patient # 10024041 - testing performed on 10/01/2024 (g) Patient # 10024093 - testing performed on 10/06 /2024 (h) Patient # 10024150 - testing performed on 10/09/2024 (i) Patient # 10024226 - testing performed on 10/15/2024 (j) Patient # 10024341 - testing performed on 10/23/2024 (k) Patient # 10024491 - testing performed on 11/04/2024 (l) Patient # 10024587 - testing performed on 11/11/2024 (m) Patient # 10024654 - testing performed on 11/17/2024 (n) Patient # 10024663 - testing performed on 11/18 /2024 (o) Patient # 10024707 - testing performed on 11/20/2024 (p) Patient # 10024627 - testing performed on 12/09/2024 (q) Patient # 10024923 - testing performed on 12/10/2024 (r) Patient # 10025013 - testing performed on 12/18/2024 (s) Patient # 10025026 - testing performed on 12/19/2024 (t) Patient # 10025037 - testing performed on 12/20/2024 (u) Patient # 10025053 - testing performed on 01/09 /2025 (v) Patient # 10025312 - testing performed on 01/14/2025 (w) Patient # 10025390 - testing performed on 01/19/2025 (x) Patient # 10025412 - testing performed on 01/21/2025 (y) Patient # 10025723 - testing performed on 02/12/2025 (z) Patient # 10025748 - testing performed on 02/14/2025 (aa) Patient # 10025841 - testing performed on 02/21/2025 (bb) Patient # 10025862 - testing performed on 02/23 /2025 (cc) Patient # 10025936 - testing performed on 02/28/2025 (dd) Patient # 10026113 - testing performed on 03/13/2025 (ee) Patient # 10026149 - testing performed on 03/16/2025 (ff) Patient # 10026238 - testing performed on 03/23/2025 (gg) Patient # 10026311 - testing performed on 03/27/2025 (hh) Patient # 10026373 - testing performed on 03/31/2025 (ii) Patient # 10026403 - testing performed on 04/02 /2025 (jj) Patient # 10026442 - testing performed on 04/06/2025 (kk) Patient # 10026462 - testing performed on 04/08/2025 (ll) Patient # 10026464 - testing performed on 04/08/2025 (mm) Patient # 10026485 - testing performed on 04/10 /2025 D5429 MAINTENANCE AND FUNCTION CHECKS CFR(s): 493.1254(a)(1) (a)(1) Maintenance as defined by the manufacturer and with at least the frequency specified by the manufacturer. This STANDARD is not met as evidenced by: -- 4 of 8 -- Based on a review of records, manufacturer's maintenance checklist, and interview with the technical consultant, the laboratory failed to ensure the manufacturer's instructions were followed for performing maintenance procedures during the review period of July 2024 through the current date. Findings include: (1) On 03/20/2026 at 11:15 am, the technical consultant stated Protime and Activated Partial Prothrombin Time testing were performed using the Sysmex CA-600 series analyzer; (2) A review of the the manufacturer's CA-600 maintenance checklist required the following maintenance procedure: (a) Yearly - "Replace Rinse Filter". (3) A review of maintenance logs from July 2024 through the current date identified the yearly maintenance had not been documented as performed between 07/01/2024 and 03/20 /2026; (4) The findings were reviewed with the technical consultant who stated on 03 /20/2026 at 11:15 am the laboratory was unable to provide documentation of maintenance performed as stated above. D5445 CONTROL PROCEDURES CFR(s): 493.1256(d)(1)(2)(g) (d) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- (d)(1) Perform control procedures as defined in this section unless otherwise specified in the additional specialty and subspecialty requirements at 493. 1261 through 493.1278. (d)(2) For each test system, perform control procedures using the number and frequency specified by the manufacturer or established by the laboratory when they meet or exceed the requirements in paragraph (d)(3) of this section. (d)(3) At least once each day patient specimens are assayed or examined perform the following for: This STANDARD is not met as evidenced by: Based on a review of records and interview with the technical consultant and testing person #1, the laboratory failed to perform QC (quality control) as stated in the IQCP (Individualized Quality Control Plan) for D-dimer testing during the review period of April 2024 through December 2025. Findings include: (1) On 03/17/2026 at 02:20 pm, the technical consultant and testing person #1 stated the following: (a) The laboratory performed D-Dimer testing using Biosite Triage Meter Pro analyzer; (b) An IQCP had been developed for the test system; (c) The laboratory performed two levels of QC materials every thirty days according to the IQCP. (2) A review of QC records from April 2024 through December 2025 identified no documentation to prove QC had been performed between 02/21/2025 and 04/21/2025; (3) The records were reviewed with the technical consultant and testing person #1 who stated on 03/18 /2026 at 03:00 pm, QC had not been performed as stated above. D5447 CONTROL PROCEDURES CFR(s): 493.1256(d)(3)(i)(g) (d)(3)(i) Each quantitative procedure, include two control materials of different concentrations; This STANDARD is not met as evidenced by: Based on a review of records and interview with the technical consultant and testing person #1, the laboratory failed to perform two levels of QC (quality control) materials for 53 of 58 days of patient High Sensitivity Troponin I testing and failed to -- 5 of 8 -- perform two levels of QC materials for one of seven days of patient Chem 8+ testing. HIGH SENSITIVITY TROPONIN I CARTRIDGE (1) On 03/17/2026 at 02:23 pm, the technical consultant and testing person #1 stated the following: (a) The laboratory began performing High Sensitivity Troponin I testing using the iSTAT1 analyzer and hs-TnI cartridge on 11/25/2025; (b) The laboratory performed QC (Qualtiy Control) materials monthly and with each new lot and new box of cartridges. (2) On 03/18 /2026, a review of records for patient testing performed during 11/25/2025 through the current date identified at least two levels of QC materials had not been performed each day of patient testing; (3) The records were reviewed with the technical consultant who stated on 03/19/2026 at 10:20 am, two levels of QC materials had not been performed each day of patient testing. (4) The following were examples of patient High Sensitivity Troponin I testing: (a) Patient # 10029310 - testing performed on 11/25/2025 (b) Patient # 10029335 - testing performed on 11/27/2025 (c) Patient # 10029402 - testing performed on 12/03/2025 (d) Patient # 10029408 - testing performed on 12/04/2025 (e) Patient # 10029409 - testing performed on 12/04/2025 (f) Patient # 10029453 - testing performed on 12/08/2025 (g) Patient # 10029477 - testing performed on 12/09/2025 (h) Patient # 10029492 - testing performed on 12/11 /2025 (i) Patient # 10029513 - testing performed on 12/12/2025 (j) Patient # 10029514 - testing performed on 12/13/2025 (k) Patient # 10029544 - testing performed on 12/15/2025 (l) Patient # 10029557 - testing performed on 12/16/2025 (m) Patient # 10029558 - testing performed on 12/17/2025 (n) Patient # 10029585 - testing performed on 12/19/2025 (o) Patient # 10029602 - testing performed on 12/20 /2025 (p) Patient # 10029607 - testing performed on 12/22/2025 (q) Patient # 10029625 - testing performed on 12/23/2025 (r) Patient # 10029641 - testing performed on 12/25/2025 (s) Patient # 10029665 - testing performed on 12/27/2025 (t) Patient # 10029702 - testing performed on 12/31/2025 (u) Patient # 10029718 - testing performed on 01/02/2026 (v) Patient # 10029747 - testing performed on 01/03 /2026 (w) Patient # 10029752 - testing performed on 01/04/2026 (x) Patient # 10029770 - testing performed on 01/06/2026 (y) Patient # 10029795 - testing performed on 01/07/2026 (z) Patient # 10029835 - testing performed on 01/10/2026 (aa) Patient # 10029861 - testing performed on 01/13/2026 (bb) Patient # 10029885 - testing performed on 01/16/2026 (cc) Patient # 10029898 - testing performed on 01/18 /2026 (dd) Patient # 10029913 - testing performed on 01/20/2026 (ee) Patient # 10029933 - testing performed on 01/21/2026 (ff) Patient # 10029947 - testing performed on 01/22/2026 (gg) Patient # 10029966 - testing performed on 01/24/2026 (hh) Patient # 10029983 - testing performed on 01/27/2026 (ii) Patient # 10030011 - testing performed on 01/29/2026 (jj) Patient # 10030026 - testing performed on 01/31 /2026 (kk) Patient # 10030039 - testing performed on 02/01/2026 (ll) Patient # 10030056 - testing performed on 02/02/2026 (mm) Patient # 10030059 - testing performed on 02/03/2026 (nn) Patient # 10030093 - testing performed on 02/05/2026 (oo) Patient # 10030129 - testing performed on 02/08/2026 (pp) Patient # 10030170 - testing performed on 02/12/2026 (qq) Patient # 10030207 - testing performed on 02/14 /2026 (rr) Patient # 10030213 - testing performed on 02/15/2026 (ss) Patient # 10030244 - testing performed on 02/17/2026 (tt) Patient # 10030272 - testing performed on 02/19/2026 (uu) Patient # 10030289 - testing performed on 02/21/2026 (vv) Patient # 10030290 - testing performed on 02/21/2026 (ww) Patient # 10030297 - testing performed on 02/22/2026 (xx) Patient # 10030362 - testing performed on 02/28 /2026 (yy) Patient # 10030381 - testing performed on 03/02/2026 (zz) Patient # 10030442 - testing performed on 03/05/2026 (aaa) Patient # 10030459 - testing performed on 03/07/2026 (bbb) Patient # 10030502 - testing performed on 03/10/2026 (ccc) Patient # 10030532 - testing performed on 03/13/2026 (ddd) Patient # 10030547 - testing performed on 03/14/2026 (eee) Patient # 10030583 - testing performed on 03 /17/2026 (fff) Patient # 10030594 - testing performed on 03/18/2026 II. CHEM 8+ -- 6 of 8 -- CARTRIDGE (1) On 03/17/2026 at 02:15 pm, the technical consultant and testing person #1 stated the following: (a) The laboratory performed Sodium, Potassium, Chloride, Ionized Calcium, Glucose, BUN (Blood Urea Nitrogen), Creatinine, Anion Gap, and Total Carbon Dioxide testing using iSTAT 1 analyzer serial number 408446 and the Chem 8+ cartridge; (b) Two levels of QC (Quality Control) materials (Level 1 and Level 3) were tested on each day of patient testing. (2) A review of QC records from January through February of 2026 identified two levels of QC materials had not been performed for one of seven days of patient testing as follows: (a) Patient #10030248 - testing performed on 02/18/2026 at 00:16am. (3) The records were reviewed with the technical consultant and testing person #1 who stated on 03/19 /2026 at 09:00 am, QC materials had not been performed each day of patient testing as stated above. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on a review of records, policies and procedures, and interview with the the technical consultant and testing person #1, the laboratory director failed to provide overall management and direction during the review period of September 2024 through the current date. Findings include: (1) The laboratory director failed to ensure verification procedures for new test systems were adequate to determine the performance characteristics for one of two new test systems introduced into the laboratory. Refer to D6013; (2) The laboratory director failed to ensure quality control programs were maintained to ensure the quality of laboratory services. Refer to D6020; (3) The laboratory director failed to ensure an approved procedure manual was available and followed by all personnel responsible for the testing process. Refer to D6031. D6013 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(3)(ii) (e)(3)(ii) Verification procedures used are adequate to determine the accuracy, precision, and other pertinent performance characteristics of the method; and This STANDARD is not met as evidenced by: Based on a review of records and interview with the technical consultant and testing person #1, the laboratory director failed to ensure verification procedures for new test systems were adequate to determine the performance characteristics for one of two new test systems introduced into the laboratory. Findings include: (1) The laboratory director failed to ensure the performance specifications had been demonstrated for one of two new test methods introduced into the laboratory in 2024. Refer to D5421. D6020 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(5) (e)(5) Ensure that the quality control and quality assessment programs are established -- 7 of 8 -- and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur; This STANDARD is not met as evidenced by: Based on a review of records and interview with the technical consultant and testing person #1, the laboratory director failed to ensure quality control program was maintained to ensure the quality of laboratory services during the review period of November 2025 through the current date. Findings include: (1) The laboratory director failed to ensure the laboratory performed two levels of QC (quality control) materials for 53 of 58 days of patient High Sensitivity Troponin I testing. Refer to D5447. D6031 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(13) (e)(13) Ensure that an approved procedure manual is available to all personnel responsible for any aspect of the testing process; and This STANDARD is not met as evidenced by: Based on a review of records, policies and procedures, and interview with the technical consultant and testing person #1, the laboratory director failed to ensure an approved procedure manual was available and followed by all personnel responsible for the testing process one of two new test systems. Findings Include: (1) The laboratory director failed to ensure the laboratory have a written procedure for one of two new test systems introduced into the laboratory. Refer to D5401. -- 8 of 8 --

Summary Statement of Deficiencies D0000 The laboratory was found out of compliance with the following CLIA Conditions: 493.803; D2016: Successful Participation 493.1407; D6000: Laboratory Director, Moderate Complexity D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the CASPER 0155D report and API (American Proficiency Institute) Performance Summaries and Comparative Evaluation records, the laboratory failed to successfully participate in a proficiency testing program for two consecutive testing events for AST (Aspartate Aminotransferase), resulting in unsuccessful performance. Refer to D2096. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) (f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a review of proficiency testing scores obtained from the CASPER 0155D report and API (American Proficiency Institute) Performance Summaries and Comparative Evaluation records, the laboratory failed to achieve satisfactory performance for AST (Aspartate Aminotransferase) for two consecutive testing events in 2025. Findings include: (1) A review of the CASPER 0155D report identified the following unsatisfactory scores for AST; (a) Second Event 2025 - 60% (b) Third Event 2025 - 60% (2) A review of the proficiency testing scores from API for 2025 confirmed the above findings. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the CASPER 0155D report and API (American Proficiency Institute) Performance Summaries and Comparative Evaluation records, the laboratory director failed to provide overall management and direction of the laboratory services. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the CASPER 0155D report and API (American Proficiency Institute) Performance Summaries and Comparative Evaluation records, the laboratory director failed to ensure successful performance in an HHS approved proficiency testing program for the analyte AST (Aspartate Aminotransferase) in two consecutive testing events in 2025. Refer to D2096. -- 2 of 2 --

Summary Statement of Deficiencies D0000 The following deficiencies are a result of a desk review of proficiency testing scores obtained from the national database and from the proficiency testing provider. The laboratory was found out of compliance with the following CLIA Conditions: 493.803; D2016: Successful Participation 493.1407; D6000: Laboratory Director, Moderate Complexity D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the CASPER 0155D report and API (American Proficiency Institute) Performance Summaries and Comparative Evaluation records, the laboratory failed to successfully participate in a Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- proficiency testing program for two of two consecutive testing events for ALT (Alanine Aminotransferase) and Total Protein, resulting in unsuccessful performance. Refer to D2096. D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) (f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a review of proficiency testing scores obtained from the CASPER 0155D report and API (American Proficiency Institute) Performance Summaries and Comparative Evaluation records, the laboratory failed to achieve satisfactory performance for the ALT (Alanine Aminotransferase) and Total Protein for two of two consecutive testing events in 2025. Findings include: (1) A review of the CASPER 0155D report identified the following unsatisfactory scores; (a) ALT (i) First Event 2025 - 20% (ii) Second Event 2025 - 60% (b) Total Protein (i) First Event 2025 - 60% (ii) Second Event 2025 - 60% (2) A review of the proficiency testing scores from API for 2025 confirmed the above findings. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the CASPER 0155D report and API (American Proficiency Institute) Performance Summaries and Comparative Evaluation records, the laboratory director failed to provide overall management and direction of the laboratory services. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the CASPER 0155D report and API (American Proficiency Institute) Performance Summaries and Comparative Evaluation records, the laboratory director failed to ensure successful performance in an HHS approved proficiency testing program for the analytes ALT (Alanine Aminotransferase) and Total Protein in two of two consecutive testing events in 2025. Refer to D2096. -- 2 of 2 --

Summary Statement of Deficiencies D0000 The recertification survey was performed on 02/29/2024. The laboratory was found in compliance with standard-level deficiencies cited. The findings were reviewed with testing person # 1, director of nursing, technical consultant, and operations manager during an exit conference performed at the conclusion of the survey. D2094 ROUTINE CHEMISTRY CFR(s): 493.841(e) (1) For any unsatisfactory analyte or test performance or testing event for reasons other than a failure to participate, the laboratory must undertake appropriate training and employ the technical assistance necessary to correct problems associated with a proficiency testing failure. (2) For any unacceptable analyte or testing event score, remedial action must be taken and documented, and the documentation must be maintained by the laboratory for two years from the date of participation in the proficiency testing event. This STANDARD is not met as evidenced by: Based on a review of records and interview with the technical consultant and testing person #1, the laboratory failed to take remedial action for unacceptable proficiency testing scores for one of six Chemistry Core events reviewed in 2022 and 2023. Findings include: (1) A review of Chemistry Core proficiency testing records for the first, second, and third events of 2022; and the first, second, and third events of 2023 event identified the following failures for one of six events reviewed: (a) First Event 2023 (i) pCO2 - The laboratory received a score of 60%. The results for samples IB- 02 and IB-03 had failed. There was no documentation to prove that remedial action had been taken for the failures; (ii) pH - The laboratory received a score of 60%. The results for samples IB-02 and IB-03 had failed. There was no documentation to prove that remedial action had been taken for the failures; (iii) pO2 - The laboratory received a score of 20%. The results for samples IB-01, IB-02, IB-03, and IB-05 had failed. There was no documentation to prove that remedial action had been taken for Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 7 -- the failures. (3) The records were reviewed with the technical consultant and testing person #1 who stated on 02/29/2024 at 11:00 am, there was no evidence that remedial action had been taken for the failures. D5211 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(a) The laboratory must review and evaluate the results obtained on proficiency testing performed as specified in subpart H of this part. This STANDARD is not met as evidenced by: Based on a review of records and interview with the technical consultant and testing person #1, the laboratory failed to review and evaluate proficiency testing results for one of six Chemistry Core proficiency testing events reviewed. Findings include: (1) A review of Chemistry Core Proficiency testing records for six events (First 2022, Second 2022, Third 2022, First 2023, Second 2023, and Third 2023) identified the following failure with no evidence that

Summary Statement of Deficiencies D0000 The following deficiencies are a result of a desk review of proficiency testing scores obtained from the national database and from the proficiency testing provider. The laboratory was found out of compliance with the following CLIA Conditions of Participation: 493.803; D2016: Successful Participation 493.1407; D6000: Laboratory Director, Moderate Complexity D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the Casper 0155D report and the proficiency testing graded evaluations obtained from American Proficiency Institute, the laboratory failed to successfully participate in a proficiency Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- testing program for the specialty of Hematology. Findings include: (1) The laboratory failed to achieve satisfactory performance for two consecutive events for the specialty of Hematology. Refer to D2130. D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the Casper 0155D report and the proficiency testing graded evaluations obtained from American Proficiency Institute, the laboratory failed to achieve satisfactory performance for White Blood Cell Differential for %Basophils, %Eosinophils, %Lymphocytes, % Monocytes, and %Neutrophils for two consecutive testing events. Findings include: (1) The laboratory received the following scores: (a) %Basophils - 0% on the third 2022 event and 20% on the first 2023 event; (b) %Eosinophils - 0% on the third 2022 event and 0% on the first 2023 event; (c) %Lymphocytes - 0% on the third 2022 event and 0% on the first 2023 event; (d) %Monocytes - 20% on the third 2022 event and 0% on the first 2023 event; (e) %Neutrophils - 0% on the third 2022 event and 0% on the first 2023 event. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the Casper 0155D report and the proficiency testing graded evaluations obtained from American Proficiency Institute, the laboratory failed to achieve satisfactory performance for White Blood Cell Differential for %Basophils, %Eosinophils, %Lymphocytes, % Monocytes, and %Neutrophils for the third 2022 event and first 2023 event. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a desk review of proficiency testing scores obtained from the Casper 0155D -- 2 of 3 -- report and the proficiency testing graded evaluations obtained from American Proficiency Institute, the laboratory failed to achieve satisfactory performance for White Blood Cell Differential for %Basophils, %Eosinophils, %Lymphocytes, % Monocytes, and %Neutrophils in two consecutive events. The laboratory failed to achieve a passing score of 80% for the third 2022 event and first 2023 event. Refer to D2130. -- 3 of 3 --

Summary Statement of Deficiencies D0000 The initial survey was performed on 03/07,08,09/2022. Immediate Jeopardy was determined during the survey due to issues identified with the iSTAT 1 analyzer using the PT (Prothrombin Time)/INR (International Normalized Ratio) cartridges. It was routinely being used to perform PT/INR testing for screening and diagnostic purposes (testing outside of the manufacturer's intended use). In addition, issues identified throughout the analytic systems contributed to the determination. The laboratory was found out of compliance with the following CLIA regulations: 493.1250; D5400: Analytic Systems 493.1403; D6000: Laboratory Director 493.1409; D6033: Technical Consultant 493.1421; D6063: Testing Personnel The findings were reviewed with the hospital administrator, directory of nursing, Labnet CEO, technical consultant, and laboratory manager during an exit conference performed at the conclusion of the survey. D2015 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(5)(6) (5) The laboratory must document the handling, preparation, processing, examination, and each step in the testing and reporting of results for all proficiency testing samples. The laboratory must maintain a copy of all records, including a copy of the proficiency testing program report forms used by the laboratory to record proficiency testing results including the attestation statement provided by the PT program, signed by the analyst and the laboratory director, documenting that proficiency testing samples were tested in the same manner as patient specimens, for a minimum of two years from the date of the proficiency testing event. (6) PT is required for only the test system, assay, or examination used as the primary method for patient testing during the PT event. This STANDARD is not met as evidenced by: Based on a review of records and interview with the laboratory manager, the laboratory director or designee failed to sign a proficiency testing attestation statement Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 40 -- for one of five events. Findings include: (1) A review of the 2021 proficiency testing records revealed for one of five events: (a) Second 2021 Chemistry Miscellaneous Event - The attestation statement had not been signed by the laboratory director or designee. (2) The findings were reviewed with the laboratory manager who stated on 03/07/2022 at 04:15 pm, the attestation statement had not been signed by the laboratory director or designee as shown above. D5203 SPECIMEN IDENTIFICATION AND INTEGRITY CFR(s): 493.1232 The laboratory must establish and follow written policies and procedures that ensure positive identification and optimum integrity of a patient's specimen from the time of collection or receipt of the specimen through completion of testing and reporting of results. This STANDARD is not met as evidenced by: Based on a review of records, manufacturer's instructions, and interview with the director of nursing, the laboratory failed to follow the manufacturer's instructions for Blood Gas and Lactate testing for 11 of 11 test reports. Findings include: (1) On 03/08 /2022 at 03:35 pm the director of nursing stated the nursing staff in the Emergency Department began performing Blood Gas (pH, pCO2, pO2) and Lactate testing using the CG4+ cartridge and iSTAT 1 analyzer on 12/09/2020; (2) A review of the manufacturer's instructions under the section titled, "Mixing and Test Timing (time from collection to cartridge fill) for Chemistry and Blood Gas Cartridge" stated, "Samples for pH, PCO2, PO2, TCO3 and ionized calcium should be tested within 10 minutes."; (3) A review of patient testing records between 07/01/2021 through 11/06 /2021 identified the following for 11 of 11 patient test reports (NOTE: Result time correlates to time sample tested): (a) Patient Report #10003255 - The collection date and time were not documented and the result date and time were 06/30/2021 at 10:16 pm; (b) Patient Report #10003273 - The collection date and time were 07/01/2021 at 07:40 pm and the result date and time were 07/01/2021 at 08:01 pm (21 minutes later); (c) Patient Report #10003289 - The collection date and time were not documented and the result date and time were 07/02/2021 at 04:06 pm; (d) Patient Report #10003307 - The collection date and time were not documented and the result date and time were 07/04/2021 at 06:07 am; (e) Patient Report #10004480 - The collection date and time were not documented and the result date and time were 09/03 /2021 at 11:04 am; (f) Patient Report #10004495 - The collection date and time were not documented and the result date and time were 09/04/2021 at 03:34 pm; (g) Patient Report #10004523 - The collection date and time were not documented and the result date and time were 09/06/2021 at 04:19 pm; (h) Patient Report #10004588 - The colleection date and time were not documented and the result and and time were 09/09 /2021 at 01:20 am; (i) Patient Report #10004586 - The collection date and time were not documented and the result date and time were 09/09/2021 at 08:03 pm; (j) Patient Report #10004626 - The collection date and time were not documented and the result date and time were 09/10/2021 at 06:05 pm; (k) Patient Report #10005675 - The collection date and time were not documented and the result date and time were 11/06 /2021 at 06:50 pm. (4) The findings were reviewed with the director of nursing. On 03 /08/2022 at 03:00 pm, the director of nursing stated the laboratory could not prove the specimen was collected and tested within 10 minutes as required by the manufacturer. D5209 PERSONNEL COMPETENCY ASSESSMENT POLICIES CFR(s): 493.1235 -- 2 of 40 -- As specified in the personnel requirements in subpart M, the laboratory must establish and follow written policies and procedures to assess employee and, if applicable, consultant competency. This STANDARD is not met as evidenced by: Based on a review of records, written policy, and interview with the laboratory manager, the laboratory failed to have a written technical consultant competency policy based on the position responsibilities as listed in Subpart M for one of one technical consultants. Findings include: (1) On 03/07/2022, a review of the competency policy titled, "Employee Yearly Competency" revealed the policy did not include guidance for assessing the competency of the technical consultant; (2) A review of personnel records for competency assessments performed during 2020 and 2021 revealed there was no evidence of a competency performed for the technical consultant based on their job responsibilities; (3) The records were reviewed with laboratory manager. The laboratory manager stated on 03/08/2022 at 04:10 pm a policy had not been written and the above competencies had not been performed. D5211 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(a) The laboratory must review and evaluate the results obtained on proficiency testing performed as specified in subpart H of this part. This STANDARD is not met as evidenced by: Based on a review of records and interview with the laboratory manager, the laboratory failed to review and evaluate proficiency testing results for three of five events. Findings include: FAILURE (1) On 03/07/2022, a review of 2021 proficiency testing records revealed the following failures: (a) Second 2021 Chemistry Core Event (i) Creatinine - The laboratory failed the results for one of five samples (IB-07); (ii) Glucose - The laboratory failed the results for one of five samples (IB-07); (iii) Hematocrit - The laboratory failed the results for one of five samples (IB-07); (iv) Hemoglobin - The laboratory failed the results for one of five samples (IB-07); (v) TCO2 - The laboratory failed the results for one of five samples (IB-07). (b) Third 2021 Chemistry Core Event (i) ALT (Alanine Aminotransferase) - The laboratory failed the results for one of five samples (CH-13); (ii) TCO2 - The laboratory failed the results for one of five samples (IB-14). (2) There was no evidence in the records proving the failures had been addressed; (3) The records were reviewed with the laboratory manager. The laboratory manager stated on 03/07/2022 at 04:05 pm

Summary Statement of Deficiencies D0000 The recertification survey was performed on 09/24/18 through 09/27/18. The findings were reviewed with chief executive officer and laboratory manager/technical consultant #2 during an exit conference performed at the conclusion of the survey. The laboratory was found to be in compliance with standard-level deficiencies cited. D2015 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(5)(6) (5) The laboratory must document the handling, preparation, processing, examination, and each step in the testing and reporting of results for all proficiency testing samples. The laboratory must maintain a copy of all records, including a copy of the proficiency testing program report forms used by the laboratory to record proficiency testing results including the attestation statement provided by the PT program, signed by the analyst and the laboratory director, documenting that proficiency testing samples were tested in the same manner as patient specimens, for a minimum of two years from the date of the proficiency testing event. (6) PT is required for only the test system, assay, or examination used as the primary method for patient testing during the PT event. This STANDARD is not met as evidenced by: Based on a review of records and interview with the laboratory manager/technical consultant #2, the laboratory failed to ensure proficiency testing attestation statements had been signed by the laboratory director or designee. Findings include: (1) On the first day of the survey, the surveyor reviewed 2017 and 2018 proficiency testing records. The following was identified for 2 of 15 testing events: (a) First 2017 Immunohematology Event (i) The attestation was not signed by the laboratory director or designee (b) Second 2017 Immunohematology Event (i) The attestation was not signed by the laboratory director or designee (c) Third 2017 Immunohematology Event (i) The attestation was not signed by the laboratory director or designee (2) The findings were reviewed with the laboratory manager Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 13 -- /technical consultant #2 who stated the attestations had not been signed as indicated above. D3017 REQUIREMENTS FOR TRANSFUSION SERVICES CFR(s): 493.1103(a) Arrangement for services. The facility must have a transfusion service agreement reviewed and approved by the responsible party(ies) that govern the procurement, transfer, and availability of blood and blood products. This STANDARD is not met as evidenced by: Based on a review of records and interview with the laboratory manager/technical consultant #2, the laboratory failed to have a transfusion service agreement between the laboratory and supplier for the procurement, transfer and availability of blood and blood products. Findings include: (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor the laboratory routinely maintained 2 units of O negative packed red blood cells and 2 units of O positive pack red blood cells in the ThermoScientific blood bank refrigerator. The units were available for emergency patient transfusions (packed red blood cells must be stored at 1-6 degrees Centigrade-C); (2) On the fourth day of the survey, the surveyor reviewed the laboratory's records for a transfusion service agreement between the laboratory and the supplier (Oklahoma Blood Institute) and identified the following: (a) An approved agreement between the laboratory and the blood supplier for the purpose of procurement, transfer and availability of blood and blood products was not available. (4) The surveyor reviewed the findings with laboratory manager/technical consultant #2 who stated a transfusion agreement between the laboratory and supplier was not available as indicated above. D3021 REQUIREMENTS FOR TRANSFUSION SERVICES CFR(s): 493.1103(c)(1) Blood and blood products storage and distribution. If a facility stores or maintains blood or blood products for transfusion outside of a monitored refrigerator, the facility must ensure the storage conditions, including temperature, are appropriate to prevent deterioration of the blood or blood product. This STANDARD is not met as evidenced by: Based on a review of records, policies and procedures, and interview with laboratory manager/technical consultant #2, the laboratory failed to ensure an adequate alarm system was in place for the blood bank refrigerator. Findings include: REFRIGERATOR ALARM CHECK (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor the laboratory routinely maintained 2 units of O negative packed red blood cells and 2 units of O positive pack red blood cells in the ThermoScientific blood bank refrigerator. The units were available for emergency patient transfusions (packed red blood cells must be stored at 1-6 degrees Centigrade-C); (2) On the second day of the survey, the surveyor reviewed the laboratory's written policy for performing alarm checks on the refrigerator. The policy required the alarm checks be performed on a quarterly basis; (3) The surveyor then reviewed the alarm check records for 2017 and 2018. It was identified that blood bank alarm checks had not been document as performed since 10 /30/17 through the second day of the survey; (4) The surveyor reviewed the records -- 2 of 13 -- with laboratory manager/technical consultant #2 who stated the blood bank alaram had not been documented as performed as indicated above. TEMPERATURE CHARTS (1) On the second day of the survey, the surveyor observed the thermograph temperature recorder for the blood bank refrigerator. The refrigerator had a recorder connected to it for continuously recording the temperature on thermograph charts (Note: units of packed cells must be stored at 1-6 degrees Centigrade). Each chart monitored the temperature for a 7 day period; (2) The surveyor reviewed 28 refrigerator charts dated from 12/26/17 through 09/09/18. The review indicated that 6 of 28 charts had not been changed by the 7th day of usage. The findings include: (a) Chart #5 - The chart was put into use on 01/22/18 and removed on 02/06/18 (15 days); (b) Chart #6 - The chart was put into use on 02/06/18 and removed 02/26/18 (16 days); (c) Chart #7 - The chart was put into use on 02/26/18 and removed 03/07/18 (9 days); (d) Chart #8 - The chart was put into use on 03/07/18 and removed 03/21/18 (14 days); (e) Chart #11 - The chart was put into use on 04/12 /18 and removed 05/01/18 (19 days); (f) Chart #27 - The chart was put into use on 07 /25/18 and removed 08/06/18 (12 days); (3) The surveyor reviewed the charts with the laboratory manager/technical consultant #2, who stated the charts had not been changed by the 7th day of usage as indicated above. D5211 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(a) The laboratory must review and evaluate the results obtained on proficiency testing performed as specified in subpart H of this part. This STANDARD is not met as evidenced by: Based on a review of records and interview with the laboratory manager/technical consultant #2, the laboratory failed to review and evaluate proficiency testing results. Findings include: (1) On the first day of the survey, the surveyor reviewed 2017 and 2018 proficiency testing records. The following biases were identified (biases were identified using the SDI (Standard Deviation Index) values assigned by the proficiency program): (a) Second 2017 Chemistry Core Event (i) LDL (Low Density Lipoprotein) - 3 of 5 results exhibited a negative bias (aa) Sample CH-06 - SDI of -2.0 (bb) Sample CH-07 - SDI of -2.1 (cc) Sample CH-09 - SDI of -2.1 (b) Second 2018 Chemistry Core Event (i) Magnesium - 3 of 5 results exhibited a positive bias (aa) Sample CH-07 - SDI of 2.8 (bb) Sample CH-09 - SDI of 2.1 (cc) Sample CH-10 - SDI of 2.2 (dd) Sample CH-10 - SDI of 3.3 (2) The surveyor could not locate evidence in the records proving the biases had been identified and addressed; (3) The records were reviewed with the laboratory manager/technical consultant #2 who stated the biases had not been addressed. D5215 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(b)(2) The laboratory must verify the accuracy of any analyte, specialty or subspecialty assigned a proficiency testing score that does not reflect laboratory test performance (that is, when the proficiency testing program does not obtain the agreement required for scoring as specified in subpart I of this part, or the laboratory receives a zero score for nonparticipation, or late return or results). This STANDARD is not met as evidenced by: -- 3 of 13 -- Based on a review of records and interview with the laboratory manager/technical consultant #2, the laboratory failed to evaluate the accuracy of testing when a proficiency result had not been graded by the proficiency program. Findings include: (1) On the first day of the survey, the surveyor reviewed 2017 and 2018 proficiency testing records and identified the following had not been evaluated by the proficiency testing program: (a) Hematology (i) 2017 second event (aa) Blood Cell Identification - BCI-13 and BCI-14 (2) The surveyor further reviewed the records and could not locate documentation verifying the laboratory had performed a self-evaluation of the non-graded results; (3) The surveyor asked the laboratory manager/technical consultant #2 if the results had been documented as evaluated. The laboratory manager /technical consultant #2 both reviewed the records and stated the non-graded results had not been documented as reviewed. D5317 SPECIMEN SUBMISSION, HANDLING, AND REFERRAL CFR(s): 493.1242(d) If the laboratory accepts a referral specimen, written instructions must be available to the laboratory's clients and must include, as appropriate, the information specified in paragraphs (a)(1) through (a)(7) of this section. This STANDARD is not met as evidenced by: Based on a review of records and interview with the laboratory manager/technical consultant #2, the laboratory failed to provide written instructions to clients collecting and referring hematology and chemistry specimens. Findings include: (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated the following to the surveyor: (a) The laboratory performed CBC (Complete Blood Count) testing using the Sysmex XS 1000i analyzer; (i) Hematology specimens were transported to the laboratory from outside home health agencies and long term care facilities. (b) The laboratory performed routine chemistry testing using the Beckman Coulter AU480 analyzer; (i) Routine chemistry specimens were transported to the laboratory from outside home health agencies and long term care facilities. (2) The surveyor asked the laboratory manager/technical consultant #2 if instructions (e.g., client service manual) had been written and provided to the home health agencies which would explain the laboratory's specimen handling policies (e.g., collection, preservation, storage, transport, testing schedule times, and how to obtain additional assistance for unusual circumstances). The laboratory manager/technical consultant #2 stated specimen handling instructions had not been written and provided to the clients. D5411 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(a) Test systems must be selected by the laboratory. The testing must be performed following the manufacturer's instructions and in a manner that provides test results within the laboratory's stated performance specifications for each test system as determined under 493.1253. This STANDARD is not met as evidenced by: Based on a review of records, manufacturer's instructions, procedure manual, and interview with the laboratory manager/technical consultant #2, the laboratory failed to follow the manufacturer's instructions. Findings include: (1) On the third day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor the -- 4 of 13 -- Sysmex CA-530 analyzer was used to perform PT/INR (Prothrombin Time /International Normalized Ratio) and PTT (Partial Thromboplastin Time) testing; (2) The surveyor reviewed the manufacturer's instructions for verifying a normal reference interval which stated: (a) "Donors must be from a healthy population (no known pathological conditions)"; (b) "Donors should not take any medications, including aspirin"; (3) The surveyor reviewed the implementation records for the analyzer. The following was identified for the current PT and PTT reagents put into use on 12/01/17 (PT Reagent - Siemens Dade Innovin lot #549708 and PTT Reagent - Siemens Actin FSL lot #556918A): (a) There was no documentation of the health status and medication history of the donors. (4) The surveyor reviewed the records with the laboratory manager/technical consultant #2 who stated there was no documentation to prove the health status and medication history of the donors. D5413 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(b) The laboratory must define criteria for those conditions that are essential for proper storage of reagents and specimens, accurate and reliable test system operation, and test result reporting. The criteria must be consistent with the manufacturer's instructions, if provided. These conditions must be monitored and documented and, if applicable, include the following: (1) Water quality. (2) Temperature. (3) Humidity. (4) Protection of equipment and instruments from fluctuations and interruptions in electrical current that adversely affect patient test results and test reports. This STANDARD is not met as evidenced by: Based on a review of records and interview with the laboratory manager/technical consultant #2, the laboratory failed to monitor temperatures; and failed to ensure the humidity was maintained as required. Findings include: SUMMIT PROFESSIONAL FREEZER (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor chemistry reagents were stored in the Summit Professional Freezer within a range of -20 to -70 degrees C (Centigrade); (2) On the third day of the survey, the surveyor reviewed the temperature records from January 2018 through June 2018 and identified the following: (a) Temperatures not documented between: (i) 01/06/18 and 01/08/18 (3) The surveyor reviewed the findings with the laboratory manager/technical consultant #2 who stated the above temperatures had not been documented. HEMATOLOGY/COAGULATION REFRIGERATOR (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor that a hematology/coagulation refrigerator was monitored daily (acceptable range 2 - 8 degrees C); (2) On the third day of the survey, the surveyor reviewed the temperature records from January 2018 through June 2018 and identified the following: (a) Temperatures not documented between: (i) 01/06/18 and 01/08/18 (ii) 04/14/18 and 04/16/18 (3) The surveyor reviewed the findings with the laboratory manager/technical consultant #2 who stated the above temperatures had not been documented. IMMUNOHEMATOLOGY REFRIGERATOR (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor that the immunohematology refrigerator was monitored daily (acceptable range 2 - 5 degrees C); (2) On the third day of the survey, the surveyor reviewed the temperature records from January 2018 through June 2018 and identified the following: (a) Temperatures not documented between: (i) 04/14/18 and 04/16/18 (3) The surveyor reviewed the findings with the laboratory manager/technical consultant #2 who stated the above temperatures had not been documented. ROOM TEMPERATURE (1) On the first day of the survey, the laboratory manager/technical -- 5 of 13 -- consultant #2 stated to the surveyor that a laboratory room temperature was monitored daily (acceptable range 18-29 degrees C); (2) On the third day of the survey, the surveyor reviewed the temperature records from January 2018 through June 2018 and identified the following: (a) Temperatures not documented between: (i) 01/06/18 and 01/08/18 (ii) 01/20/18 and 01/22/18 (3) The surveyor reviewed the findings with the laboratory manager/technical consultant #2 who stated the above temperatures had not been documented. SYSMEX CA-500 HUMIDITY (1) On the first day of the survey, the laboratory manager stated the following to the surveyor: (a) PT (Prothrombin Time)/INR (International Normalized Ratio) and PTT (Partial Thromboplastin Time) testing was performed using the Sysmex CA-500 analyzer. (2) On the third day of the survey, the surveyor reviewed the manufacturer's environmental requirements for the analyzers. The manufacturer required the relative humidity be maintained within the range of 30-85%; (3) The surveyor reviewed laboratory records from January 2018 through June 2018 and identified daily monitoring of humidity was less than 30% for the following dates: (a) January 2018 - Days 1,3,4,5,6,12,13,14,15,16,17,18,19,19,22,23,24,25,26,27,29,30,31 (b) February 2018 - Days 2,3,4,5,6,7,8,9,11,12,13,19,21,27 (c) March 2018 - Days 6,8,9,10,14,15,21 (d) April 2018 - Days 7,8,16,17 (4) The surveyor reviewed the storage requirements with the laboratory manager/technical consultant #2, who stated the humidity had not been maintained as required by the manufacturer. D5421 ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(1) Each laboratory that introduces an unmodified, FDA-cleared or approved test system must do the following before reporting patient test results: (1)(i) Demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (1)(i)(A) Accuracy. (1)(i) (B) Precision. (1)(i)(C) Reportable range of test results for the test system. (1)(ii) Verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population. This STANDARD is not met as evidenced by: The Based on a review of records and interview with the laboratory manager/technical consultant #2, the laboratory failed to demonstrate the performance specifications for a new test kit. Findings include: (1) At the beginning of the survey, the laboratory manager/technical consultant #2 stated to the surveyor that the laboratory recently obtained the Henry Schein One Step+ Combo test kit to perform patient pregnancy (HCG) testing. The surveyor then asked laboratory manager/technical consultant #2 to verify what specimen type the laboratory used for the testing. The laboratory manager /technical consultant #2 stated that serum samples would be used to perform the testing (classifying the test as non-waived); (2) On the second day of the survey, the surveyor asked the laboratory manager/technical consultant #2 for the date the serum pregnancy test kit had been put into use for patient testing; and for records to substantiate that the performance specifications (e.g., accuracy, precision) had been demonstrated for the test kit before it had been put into use. The laboratory manager /technical consultant #2 stated the following: (a) The test kit had been put into use for patient testing on 04/06/18; (b) The performance specifications had not been demonstrated for the test kit before it was put into use. (3) The surveyor then reviewed laboratory records and identified that eight patient serum pregnancy tests had been performed and reported using the new test kit as follows: (a) Testing performed on 04 /25/18 (b) Testing performed on 04/27/18 (c) Testing performed on 05/03/18 (d) -- 6 of 13 -- Testing performed on 05/06/18 (e) Testing performed on 05/20/18 (f) Testing performed on 07/11/18 (g) Testing performed on 08/01/18 (h) Testing performed on 08/12/18 NOTE: The deficiency was cited on the previous recertification survey performed on 02/28/17 through 03/02/17 D5429 MAINTENANCE AND FUNCTION CHECKS CFR(s): 493.1254(a)(1) For unmodified manufacturer's equipment, instruments, or test systems, the laboratory must perform and document maintenance as defined by the manufacturer and with at least the frequency specified by the manufacturer. This STANDARD is not met as evidenced by: Based on a review of records, manufacturer's instructions, and interview with the laboratory manager/technical consultant #2, the laboratory failed to follow the manufacturer's instructions for performing maintenance procedures. Findings include: HEMATOLOGY (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor that CBC (Complete Blood Count) testing was performed on the Sysmex XS-1000i analyzer; (2) On the second day of the survey, the surveyor reviewed the manufacturer's maintenance requirements as stated on the manufacturer's maintenance logs. The requirement for weekly maintenance was as follows: (a) Power Down IPU (3) The surveyor then reviewed maintenance records for 13 months (August 2017 through August 2018). There was no evidence the weekly maintenance had been performed: (a) Between 08/26/17and 09/10/17 (b) Between 10/20/17 and 11/11/17 (c) Between 02/14/18 and 03/01/18 (d) Between 03/14 /18 and 04/04/18 (e) Between 06/22/18 and 07/09/18 (f) Between 07/26/18 and 08/10 /18 (4) The surveyor reviewed the records with the laboratory manager/technical consultant #2, who stated the maintenance had not been performed as required. COAGULATION (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor that PT/INR (Protime/International Normalized Ratio) and PTT (Partial Thromboplastin Time) testing was performed on the Sysmex CA-500 analyzer; (2) One the second day of the survey, the surveyor reviewed the manufacturer's maintenance requirements as stated on the manufacturer's maintenance logs. The requirements for maintenance were as follows: (a) Daily (i) Turn instrument off, then on (ii) Empty Waste bottle (iii) Replensish diH2O in Rinse Bottle (iv) Replenish Reaction Tubes (v) Empty Reaction Tube Trash drawer (vi) Wipe Probe with Alcohol Swab (vii) Check and drain Penumatic Trap Chamber (viii) Replace CA Clean 1 (ix) Rinse Probe with CA CLEAN (x) Check Temperatures (Sysmex-Temp) (b) Weekly (i) Clean diH2O Rinse Bottle with Alcohol (c) Monthly (i) Replace Reagent Bottles (3) The surveyor then reviewed maintenance records for 8 months (January 2018 through August 2018). There was no evidence the following maintenance had been documented as performed: (a) Daily (i) Between 06/14/18 and 06/17/18 (b) Weekly (i) Between 06/17/18 and 07/11/18 (c) Monthly (i) Between 01 /03/18 and 03/01/18 (ii) Between 03/01/18 and 05/03/18 (4) The surveyor reviewed the records with the laboratory manager/technical consultant #2, who stated the maintenance had not been performed as required. CHEMISTRY - BECKMAN COULTER AU480 (1) On the first day of the survey, the laboratory manager /technical consultant #2 stated to the surveyor that *CMP, Lipid profile (Total Cholesterol, High Density Lipoprotein Cholesterol, Triglyceride), A1C, GGT (Gamma-Glutamyl Transpeptidase), Gentamicin, Vancomycin, Acetaminophen, Ethanol, Ammonia, Salicylate, Iron, Digoxin, Dilantin, Amylase, Lipase, Total Bilirubin, Magnesium testing were performed on the Beckman Counter AU480 -- 7 of 13 -- analyzer; (2) On the second day of the survey, the surveyor reviewed the manufacturer's maintenance requirements as stated on the manufacturer's maintenance logs. The requirements for maintenance were as follows: (a) Daily (i) Inspect the Syringes for Leaks (ii) Inspect he Wash Solution Roller Pump for Leaks (iii) Inspect, Clean and Prime the Sample Probe, Reagent Probe, and Mix Bars (iv) Inspect the Wash Solution and Replenish As Needed (v) Inspect the Printer (Option) and Paper (vi) Replace the DI water or diluent in the Pre-dilution Bottle (vii) Inspect the Stability of the Upper Cover (viii) Prepare the Sample Probe Wash Solutions (ix) ISE Cleaning (x) ISE Calibration (b) Weekly (i) Clean the Sample Probe and Mix Bars (ii) Perform a W2 (iii) Perform a Photocal (iv) Clean the Pre-dilution Bottle (v) Check Selectivity of the Na/K Electrodes (vi) Enhanced Cleaning of ISE Electrode Line (3) The surveyor then reviewed maintenance records for 8 months (January 2018 through August 2018). The following was identified: (a) There was no evidence the daily maintenance had been performed: (a) Between 01/23/18 and 01/25/18 (b) Between 01 /27/18 and 01/31/18 (c) Between 02/16/18 and 02/18/18 (d) Between 03/21/18 and 03 /23/18 (e) Between 06/08/18 and 06/10/18 (f) Between 06/22/18 and 06/24/18 (g) Between 07/05/18 and 07/07/18 (h) Between 07/20/18 and 07/23/18 (i) Between 07/23 /18 and 07/27/18 (b) There was no evidence the weekly maintenance had been performed: (i) Between 01/18/18 and 02/01/18 (4) The surveyor reviewed the records with the laboratory manager/technical consultant #2, who stated the maintenance had not been performed as required. *Comprehensive Metabolic Panel (CMP) - Albumin, Alkaline Phosphatase, ALT, AST, BUN, Calcium, Chloride, CO2, Creatinine, Glucose, Potassium, Sodium, Total Bilirubin and Total Protein CHEMISTRY - BECKMAN COULTER ACCESS II (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor that CKMB, Troponin I, TSH (Thyroid Stimulating Hormone), FT4 (Thyroxine), PSA (Prostate Specific Antigen), Ferritin, Folate, Vitamin B12 and Vitamin D testing were performed on the Beckman Coulter Access II analyzer; (2) On the second day of the survey, the surveyor reviewed the manufacturer's maintenance requirements as stated on the manufacturer's maintenance logs. The requirements for daily and weekly maintenance were as follows: (a) Daily (i) Check Zone Temperatures (ii) Check System Supplies (iii) Empty Liquid Waste Bottles (iv) System Backup Successful? (v) Inspect Fluidic Module (vi) Clean Probe Exteriors (vii) Prime Substrate (viii) Run Daily Clean System (b) Weekly (i) Clean Instrument Exterior (ii) Inspect Liquid Waste Bottle (iii) Check Waste Filter Bottle (iv) Inspect/Clean Primary Probe (v) Replace/Clean Primary Probe (vi) Replace/Clean Aspirate Probe (vii) Run System Check (3) The surveyor then reviewed maintenance records for 8 months (January 2018 through August 2018). The following was identified: (a) There was no evidence the daily maintenance had been performed: (a) Between 01/28/18 and 01/31/18 (b) Between 02 /18/18 and 02/20/18 (c) Between 07/20/18 and 07/22/18 (d) Between 08/01/18 and 08 /03/18 (e) Between 08/17/18 and 08/20/18 (b) There was no evidence the weekly maintenance had been performed: (i) Between 02/02/18 and 03/03/18 (ii) Between 03 /17/18 and 03/31/18 (iii) Between 03/31/18 and 04/12/18 (iv) Between 04/12/18 and 05/09/18 (v) Between 07/23/18 and 08/07/18 (vi) Between 08/11/18 and 08/24/18 (4) The surveyor reviewed the records with the laboratory manager/technical consultant #2, who stated the maintenance had not been performed as required. D5439 CALIBRATION AND CALIBRATION VERIFICATION CFR(s): 493.1255(b) Unless otherwise specified in this subpart, for each applicable test system the laboratory must do the following: Perform and document calibration verification procedure - (b)(1) Following the manufacturer's calibration verification instructions; -- 8 of 13 -- (b)(2) Using the criteria verified or established by the laboratory under 493.1253(b)(3) -- (b)(2)(i) Including the number, type, and concentration of the materials, as well as acceptable limits for calibration verification; and (b)(2)(ii) Including at least a minimal (or zero) value, a mid-point value, and a maximum value near the upper limit of the range to verify the laboratory's reportable range of test results for the test system; and (b)(3) At least once every 6 months and whenever any of the following occur: (b)(3)(i) A complete change of reagents for a procedure is introduced, unless the laboratory can demonstrate that changing reagent lot numbers does not affect the range used to report patient test results, and control values are not adversely affected by reagent lot number changes. (b)(3)(ii) There is major preventive maintenance or replacement of critical parts that may influence test performance. (b)(3)(iii) Control materials reflect an unusual trend or shift, or are outside of the laboratory's acceptable limits, and other means of assessing and correcting unacceptable control values fail to identify and correct the problem. (b)(3)(iv) The laboratory's established schedule for verifying the reportable range for patient test results requires more frequent calibration verification. This STANDARD is not met as evidenced by: Based on a review of records and interview with the laboratory manager/technical consultant #2, the laboratory failed to perform calibration verification procedures at least once every 6 months. Findings include: (1) On the first day of the survey, the laboratory manager/technical consultant #2 stated to the surveyor Ethanol and Ammonia testing were performed using the Beckman Coulter 480 analyzer; (2) On the third day of the survey, the surveyor requested 2017 and 2018 calibration verification records for the analyzer (since calibration procedures were not routinely performed, calibration verification procedures, using three or more levels of calibration materials, were required every 6 months). The laboratory manager /technical consultant #2 provided documentation that verified calibration verification procedures had not been document as performed between 01/14/18 through the third day of the survey, 09/26/18 (due in June 2018). (3) The surveyor reviewed the records with the laboratory manager/technical consultant #2 who stated calibration verification procedures had not been performed every six months as indicated above. D5783